

In the Claims:

Please amend the claims as shown in the following listing of claims, which will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

12. (New) A method of treating heart disease in a mammal comprising administering to the mammal an inhibitor of PI3Kgamma.

13. (New) The method of claim 12, wherein the inhibitor of PI3Kgamma is inactive P13Kgamma, an inactive fragment of P13Kgamma, an antibody to PI3Kgamma, or an antisense oligonucleotide that inhibits the expression of PI3Kgamma.

14. (New) The method of claim 12, wherein the inhibitor of PI3Kgamma is wortmannin, Ly294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), quercetin, or a derivative or analogue of any of these.

15. (New) The method of claim 12, wherein the heart disease is an acute coronary syndrome, a cardiac arrhythmia, or hypertension.

16. (New) The method of claim 15, wherein the heart disease is congestive heart failure, angina, myocardial infarction (heart attack), atrial flutter, atrial fibrillation, paroxysmal supraventricular tachycardia, or idiopathic hypertrophic subaortic stenosis.

17. (New) A pharmaceutical composition comprising an inhibitor of PI3Kgamma and a carrier.

18. (New) The pharmaceutical composition of claim 17, wherein the inhibitor of PI3Kgamma is inactive P13Kgamma, an inactive fragment of P13Kgamma, an antibody to PI3Kgamma or an antisense oligonucleotide that inhibits the expression of PI3Kgamma.

19. (New) The pharmaceutical composition of claim 17, wherein the inhibitor of PI3Kgamma is wortmannin, Ly294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), quercetin, or a derivative or analogue of any of these.

20. (New) A method for identifying a compound that inhibits the binding of a PI3Kgamma protein to its substrate for treatment of heart disease comprising:

- a) incubating (i) a candidate compound; (ii) a PI3Kgamma protein; and (iii) a PI3Kgamma substrate under conditions which permit the binding of PI3Kgamma protein to the substrate;
 - b) assaying for complexes of PI3Kgamma protein and the substrate or metabolites thereby produced and comparing to a control, wherein a reduction of complexes or metabolites indicates that the candidate compound has an effect on the binding of the PI3Kgamma protein to the substrate; and
 - c) determining whether the candidate compound is useful for treatment of heart disease.
21. (New) The method of claim 20, further comprising identifying a compound useful for the treatment of heart disease.
22. (New) The method of claim 21, further comprising manufacturing the compound useful for the treatment of heart disease.
23. (New) The method of claim 21, further comprising incorporating the compound useful for the treatment of heart disease in a pharmaceutical composition.
24. (New) The method of claim 21, further comprising administering the compound useful for the treatment of heart disease to a subject.
25. (New) A compound identified according to claim 20.